Search Results

Danaher Corporation, a global science and technology innovator, launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI.

TriLink BioTechnologies, a Maravai™ LifeSciences company and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery.

Inhibitor Therapeutics, Inc. has entered into an exclusive, worldwide licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930 “New Angiogenesis Inhibitors”.

Exagen Inc., a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced the execution of an exclusive license agreement.

Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.

Unravel Biosciences, Inc., (“Unravel”), an AI-enabled therapeutics company established to advance drugs for complex diseases, and the Pitt Hopkins Research Foundation (the “Foundation”) today announced a collaboration to conduct a proof of concept clinical trial of vorinostat (RVL-001) in patients with Pitt Hopkins Syndrome (PTHS).

Histogen Inc. (HSTO) today announced that the company has signed an exclusive license agreement with Johns Hopkins University.

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”) is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine (“JHU”) to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 (“CMND-100”).

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of Medicine.

Neuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome.